New developments in plasma fractionation and virus inactivation

Area of Science:

• Biochemistry
• Virology
• Biotechnology

Background:

• Ethanol fractionation has been the standard for therapeutic protein preparation from human plasma for 50 years.
• While successful, newer techniques are emerging, prompting an evaluation of their economic viability and efficacy.
• Ensuring safety includes developing methods to remove or inactivate viruses, especially small, non-enveloped types, and assessing risks from prion diseases.

Purpose of the Study:

• To evaluate the potential of newer techniques to replace or supplement ethanol fractionation for plasma protein preparation.
• To assess the economic benefits of alternative methods compared to established ethanol fractionation.
• To investigate the effectiveness of fractionation methods in removing or inactivating viral pathogens and prion agents.

Main Methods:

• Review of existing literature on ethanol fractionation and emerging plasma separation technologies.
• Economic analysis comparing the costs and benefits of traditional versus novel methods.
• Experimental assessment of the removal/inactivation efficiency of different fractionation techniques against specific viral surrogates and prion models.

Main Results:

• Ethanol fractionation is a well-established, cost-effective method for protein purification.
• Newer techniques show promise but require further validation regarding economic feasibility and broad pathogen removal.
• Preliminary data suggest fractionation processes can remove agents of spongiform encephalopathies, though viral removal, particularly for small, non-enveloped viruses, remains a challenge.

Conclusions:

• Ethanol fractionation remains a cornerstone in plasma protein therapeutics, but economic and safety considerations drive the search for alternatives.
• Future methods must demonstrate clear economic advantages and superior safety profiles, especially concerning difficult-to-remove viral agents.
• Further research is needed to confirm the efficacy of novel fractionation techniques in mitigating risks associated with blood product transmission.